91ÌìÌÃ

91ÌìÌà announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV

Published on 06/11/2018

Lyon, November 06, 2018 – 91ÌìÌÃ, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. 91ÌìÌà will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.

Read next in 'Press releases'

• 91ÌìÌà appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
• 91ÌìÌà nomme Jeff George Président du Conseil d’Administration pour soutenir sa prochaine phase de croissance et la préparation à la Phase 3
• 91ÌìÌà announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
• 91ÌìÌà annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
• 91ÌìÌà annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1